Artificial Intelligence in Healthcare: Innovation and Costs in Economic Policy

The integration of artificial intelligence-based predictive models to estimate the prognosis of complex diseases, such as ovarian cancer using microRNAs, redefines the debate on resource efficiency in Brazilian supplementary and public healthcare. This technological innovation occurs at a time when the Selic rate remains flat at 14.00% per year, as recorded on 09/16/2026, requiring extremely rigorous capital allocation from companies and the biotechnology sector. The pursuit of early diagnoses represents not only an unquestionable clinical advancement, but also a fundamental macroeconomic strategy to mitigate the systemic rising costs of late oncological treatments, which directly pressure the operational costs of health insurance operators and the State budget. To gauge the financial impact of this technological transition, one must observe the recent behavior of inflation and exchange rates on the national scene. The 12-month accumulated IPCA registers 4.44% (ref. 07/01/2026), presenting a downward trajectory compared to the reading 30 days ago when it marked 4.31% (based on a previous 4.64% reference), although it fluctuated slightly against 4.23% from about 7 days prior. Simultaneously, the commercial dollar quoted at R$ 5.2236 on 08/14/2026 demonstrates an upward variation of 2.12% in the 7-day window (compared to 5.115 reais on 08/05) and 0.73% in 30 days. This exchange rate volatility directly increases the cost of importing advanced technological inputs, laboratory reagents, and genetic sequencing tools essential for the practical application of these new artificial intelligence algorithms. This panorama of innovation under capital restriction connects directly with recent discussions mapped in the portal's editorial archive, which accumulates analyses on the hidden cost of institutional disputes and the aging demographics of the Brazilian electorate. The third consecutive negative news about systemic pressures in the country's infrastructure highlights that population aging increases the demand for high-performance health technologies, creating a supply and demand shock. From the perspective of the value tradition and margin of safety inspired by Graham and Buffett's investment philosophy, the adoption of new technologies demands extreme caution: investors and healthcare managers must distinguish speculative fads from biotechnological assets that generate real and lasting economic value, avoiding the risk of permanent capital losses in business models not yet validated on a large scale. The structural causes of this technological race involve the urgent need to cut waste in the healthcare system, where late interventions absorb disproportionate shares of the corporate and public budget. However, execution risks are high, since microRNA-based models still lack validation in large and diverse population cohorts. With the Selic rate at 14.00% per year, the opportunity cost of capital is extremely high, meaning that any miscalculation in the implementation of health innovation projects could compromise the solvency of smaller companies in the medical technology sector and health-focused fintechs. Capital discipline thus becomes the only viable defense against premature cash burning in high-interest environments. Looking toward the 30, 90, and 180-day horizon, the market d